title: Protective Role of Silymarin on Hepatic and Renal Toxicity Induced by MTX Based Chemotherapy in Children with Acute Lymphoblastic Leukemia.
abstract: BACKGROUND
  ALL is the most common childhood malignancy. The children with ALL are treated with methotrexate (MTX) based chemotherapy protocols. MTX causes unpredictable serious hepatic and renal side effects. Silymarin has antioxidant and anti-inflammatory activities and stimulates tissue regeneration. This study aims to evaluate the protective effects of Silymarin on MTX-based chemotherapy-induced Hepatic and renal toxicity in children with ALL.
  
  
  METHODS
  80 children with newly diagnosed ALL were enrolled in the study. They were randomly divided into two groups. Group I included 40 children with ages ranging from 4-13 years and the mean age of 6.85± 2.89 years, who received Silymarin 420 mg/day in 3 divided doses for one week after each MTX dose. Group II included 40 children, with ages ranging from 4-12 years and the mean age of 7.30±2.6 years, who received placebo for one week after MTX therapy. For all patients liver functions including serum bilirubin, total proteins, albumin, globulin and albumin-globulin ratio, alkaline phosphatase, ALT and AST, prothrombin time and activity and renal functions including blood urea and serum creatinine, serum cystatin C and urinary N-acetyl-beta-D-glucosaminidase were done to assess hepatic and renal toxicity before and after chemotherapy.
  
  
  RESULTS
  There were no significant differences between group I and II as regard liver and renal functions before chemotherapy. After chemotherapy, there were significantly higher values of ALT and AST and alkaline phosphatase, and significantly lower Prothrombin activity in group II compared with group I. No significant differences between group I and II were found in total bilirubin, serum protein, and albumin levels. There was significantly lower blood urea, serum creatinine, and cystatin C and urinary N-acetyl-beta-D-glucosaminidase in group I compared with group II.
  
  
  CONCLUSIONS
  Silymarin improved some hepatic and renal functions in children with ALL who received MTX-based chemotherapy protocols.
  
  
  CONCLUSIONS
  Extensive multicenter studies could be recommended to prove the hepatic and renal protective effects of Silymarin in patients with ALL who received MTX-based chemotherapy protocols.
authors.affiliation: Pediatrics, Faculty of Medicine, Tanta University.
authors.forename: Adel A
authors.initials: AA
authors.lastname: Hagag
authors.affiliation: Pediatrics, Faculty of Medicine, Tanta University.
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Elgamsy
authors.affiliation: Pediatrics, Faculty of Medicine, Tanta University.
authors.forename: Hassan M
authors.initials: HM
authors.lastname: El-Asy
authors.affiliation: Clinical Pathology, Faculty of Medicine, Tanta University.
authors.forename: Maaly M
authors.initials: MM
authors.lastname: Mabrouk